For the latest COVID-19 Travel restrictions and recommendations please click here

About the Conference:

The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new oncology therapeutics has never been greater.
Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one.
Taking almost 12 years and costing approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time.

With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation Into human subjects?

Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.

This event will feature industry experts who will debate current developments in the area, discuss the latest innovative approaches and explore future trends.

Benefits of attending

Hear first hand accounts of the most recent research in the field
See how industry leaders are using the latest technology in commercial settings
Review the latest in regulatory guidelines from European and US experts
Hear new innovative technological developments
Discuss preventative measures in drug failures
Understand the potential value of your product
Explore opportunities in partnerships


Hear from our expert speakers, including:

Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
Peter Eggelton, Medical Director Oncology, Merck
Paul McSheehy, Director Oncology, Novartis
Anthony M Giamis, Head of Radiochemistry, Abbott
Christopher Foley, Imaging ManagerGlaxoSmithKline
Simon Walker-Samuel, Senior Research Associate, University College London
Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK






VPs, Chief Scientists, Directors, Senior Managers, Principal Scientists working in...

• Imaging in cancer drug development
• Molecular imaging
• Cancer research
• Clinical development
• Drug discovery
• Clinical research
• Translational Medicine
• Drug discovery
• Radiological
• Clinical pharmacology
• Radiochemistry
• Clinical operations
• Regulatory
• Modelling and Simulation                                                             


Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Anthony  Giamis

Anthony Giamis, Head of PET/SPECT Radiochemistry, Abbott Laboratories

9:10 Translational imaging in oncology: conventional and novel imaging biomarker use for discovery and development

Anthony  Giamis

Anthony Giamis, Head of PET/SPECT Radiochemistry, Abbott Laboratories

  • Current needs for drug development
  • Imaging modalities in oncology (preclinical and clinical)
  • In-house and recent examples
  • The future of imaging biomarkers in oncology
  • 9:50 Imaging in cancer drug development – Clinical trial regulation in the EU

     Brian Davis

    Brian Davis, Consultant on Clinical Trials, MHRA

  • Is it a clinical trial?
  • Authorisation and safety reporting issues
  • Potential changes to clinical trial requirements
  • 10:30 Morning Coffee

    11:00 VISCOVER™: innovative contrast agents for in vivo small animal imaging in drug discovery

    Raif Yuecel

    Raif Yuecel, Global Product Manager, Miltenyi Biotec GmbH

  • Innovative contrast agents for MRI, CT, ultrasound, and optical imaging
  • Ready-to-use with step-by-step instructions: as easy as ABC
  • Optimized for your preclinical research in mouse and rat
  • Hassle-free contrast agents with reliable results
  • Excellent tolerability – only 100 μL injection volume
  • Committed to the “3 R’s” of animal research
  • 11:30 PET imaging with radiolabeled monoclonal antibodies and tyrosine kinase inhibitors: Immuno-PET and TKI-PET

    Guus  van Dongen

    Guus van Dongen, Project Leader , VU University Medical Center

  • Technical developments in immuno-PET and TKI-PET will be described and their clinical potential discussed
  • An overview is provided of the most appealing preclinical immuno-PET and TKI-PET studies
  • As well as the first clinical achievements with this emerging technology
  • 12:00 Toward better imaging interpretation and management to leverage oncology clinical trial success rates

    Nicolas Dano

    Nicolas Dano , Pharma Business Development Manager , MEDIAN Technologies

  • Identifying adequate endpoints and criteria to better assess a new molecule
  • Reducing data loss and collection burden while improving data quality to decrease trial duration and operational costs
  • Reducing the variability of measures for better outcome quality and decision making
  • Empowering investigator sites with advanced and standardized image analysis capabilities, therefore reducing the need of independent review and associated related issues
  • 12:30 Networking Lunch

    14:00 Contrast-enhanced ultrasound: new opportunities in drug development and clinical practice

    Francois Tranquart

    Francois Tranquart, General Manager, Bracco Imaging Spa

  • CEUS can accelerate the drug development process by providing functional, morphological, and molecular characterization
  • CEUS methods are clinically translatable
  • Current challenges will be described
  • 14:40 Enhanced Bioluminescence pre-clinical imaging with engineered Luciferases and novel Luciferin analogues

    Martin Pule

    Martin Pule, Senior Lecturer in Haematology, UCL Cancer Institute

  • Bioluminescence, a rapid, low-cost and highly sensitive imaging modality allows facile longitudinal and semi-quantitative tracking of labelled cells non-invasively.
  • The effects of codon optimization and protein stabilization on Luciferase expression in mammalian cells and their impact on bioluminescence imaging will be presented.
  • Developments include: Colour-shifted Luciferase mutants (green to red) and the combination of stabilized, red shifted Luciferases with novel Luciferins.
  • These promise to deliver higher sensitivity and multi-parametric in vivo bioluminescence imaging for drug discovery.
  • 15:20 Afternoon tea

    15:50 A powerful new imaging modality for cancer research: Multispectral Optoacoustic Tomography (MSOT)

    Christian  Wiest

    Christian Wiest, Managing Director, iThera Medical

  • Background on MSOT technology
  • Cancer-related questions addressable with MSOT imaging
  • Use of optoacoustic probes for molecular-specific contrast
  • Current data from tumour studies
  • Comparison with other preclinical imaging modalities
  • Future directions, translation into clinical applications
  • 16:30 Oncology translational imaging for early phase anticancer drug development

    Sabin Carme

    Sabin Carme, Oncology Science Clinical Imaging Manager, Pharma'Image

  • Current needs for drug development and introduction to translational approach
  • Preclinical validation for the best imaging biomarker (example with PET and MRI)
  • Flexible cinical imaging study design (example with PET and MRI)
  • Quantitative imaging data interpretation (example with PET and MRI)
  • Back translation
  • 17:10 Chairman's Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Werner Scheuer

    Werner Scheuer, Group Leader, Preclinical Optical Imaging, Pharmacology TR-PD, Pharmaceutical Research, Roche Diagnostics

    9:10 Non-invasive imaging of barriers to drug delivery

    Simon Walker-Samuel

    Simon Walker-Samuel, Research Fellow, University College London

  • Using magnetic resonance imaging to assess blood flow without a contrast agent
  • Mapping extra-vascular convection
  • Combining measures to assess interstitial pressure and drug delivery profiles
  • 9:50 Non-invasive imaging of lung tumours in preclinical models

    Francois Lassailly

    Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK

  • Longitudinal quantification using Bioluminescence and micro-CT imaging
  • Advantages and limitations of the approaches
  • Ongoing developments: image processing and quantification
  • 10:30 Morning Coffee

    11:00 Changes in tumour T1 as an example of a useful early response marker to therapy

    Paul McSheehy

    Paul McSheehy, Lab Head & International Project Team Representative, Novartis

  • Case study: using MRI to identify Tumour T1 as a biomarker
  • Tumour T1 reflects cell kill and is a generic biomarker of response
  • Potential effectiveness of this identification method in clinical trials
  • 11:40 Application of different imaging modalities in preclinical pharmacodynamics and pharmacokinetics

    Werner Scheuer

    Werner Scheuer, Group Leader, Preclinical Optical Imaging, Pharmacology TR-PD, Pharmaceutical Research, Roche Diagnostics

  • Utility and limitations of different imaging modalities in preclinical cancer models
  • Assessing tumour growth, metastasis, angiogenesis by optical imaging
  • Future aspects and translational research
  • 12:20 Networking Lunch

    13:50 Multi-centre imaging in the context of clinical trials

  • Through numerous oncology studies, our GSK imaging team, Vesalius, have gained unique perspective on managing multi-centre clinical trials and their associated challenges
  • In this presentation, we will discuss what has worked well with our imaging model and trends that we have noted in our studies
  • Christopher Foley

    Christopher Foley, Clinical Imaging Manager, GlaxoSmithKline

    John Farrell

    John Farrell, Clinical Development Director, GlaxoSmithKline

    14:30 Comprehensive data and image management tool for multicenter clinical trials

    Sharok Kimiaei

    Sharok Kimiaei, CEO, Developer of ABX-DIRECT, InfoGoSoft

  • ABX-DIRECT: a modular image transfer and management tool optimized for image intensive clinical trials and image core labs.
  • Using modular solutions to overcome web application shortcomings
  • How to effectively replace manual and semi-manual data transfer
  • 15:10 Afternoon Tea

    15:40 Analysis of problems experienced by pharmaceutical companies handling oncology imaging

  • Benchmarking of expertise
  • Optimal cooperation with an IRO
  • Common practical problems and how to avoid or manage them
  • Peter Eggleton

    Peter Eggleton, Medical Director, Merck

    Oliver Bohnsack

    Oliver Bohnsack, Senior Director Medical Affairs, Head of Oncology, Head of Medical Relations Europe, Perceptive Informatics

    16:20 Understanding the value of your product

    Brian Lovatt

    Brian Lovatt, Managing Director & Chief Executive, Vision Healthcare

  • Understanding the value of the product in development
  • Pricing & reimbursement issues
  • Competition in the market – is there a place for so many products?
  • Comparative value is the key
  • 17:00 Chairman’s Closing Remarks and Close of Day Two


    Copthorne Tara Hotel

    Scarsdale Place
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.




    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out